Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.57 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.57 |
| ▸ | THPO | P40225 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21056133 | 0.84 | ALDH1A1 (0.62) | MAPTALDH1A1PTGS1PTGS2SMN1; SMN2 | |
| SCHEMBL2420009 | 0.84 | ALDH1A1 (0.62) | MAPTALDH1A1PTGS1PTGS2SMN1; SMN2 | |
| SCHEMBL13653042 | 0.84 | MAPT (0.62) | MAPTALDH1A1PTGS1PTGS2SMN1; SMN2 | |
| SCHEMBL4037544 | 0.79 | MAPT (0.55) | MAPTALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL5530166 | 0.79 | MAPT (0.55) | MAPTALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL7040464 | 0.77 | MAPT (0.76) | MAPTALDH1A1PTGS1PTGS2SMN1; SMN2 | |
| SCHEMBL31441027 | 0.77 | PTGS1 (0.76) | MAPTALDH1A1PTGS1PTGS2SMN1; SMN2 | |
| SCHEMBL7488737 | 0.77 | PTGS1 (0.76) | MAPTALDH1A1PTGS1PTGS2SMN1; SMN2 | |
| SCHEMBL1887586 | 0.77 | MAPT (0.76) | MAPTALDH1A1PTGS1PTGS2SMN1; SMN2 | |
| SCHEMBL31318264 | 0.77 | MAPT (0.76) | MAPTALDH1A1PTGS1PTGS2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951663-B1 | (R)-ARYLKYLAMINO DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPÉ FARMACEUTICI S P A (IT) | 2016-07-20 | — | — | EP | disclosed |
| CN-101360706-B | (R) -arylalkylamino derivatives and pharmaceutical compositions thereof | DOMPE PHA R MA SPA RES & MFG | 2013-10-02 | — | — | CN | disclosed |
| US-8026367-B2 | (R)-arylalkylamino derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2011-09-27 | — | — | US | disclosed |
| US-20090124664-A1 | (R)-Arylalkylamino Derivatives and Pharmaceutical Compositions Containing Them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2009-05-14 | — | — | US | disclosed |
| CN-101360706-A | (R) -arylalkylamino derivatives and pharmaceutical compositions thereof | DOMPE PHA R MA SPA RES & MFG (IT) | 2009-02-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124664-A1 | (R)-Arylalkylamino Derivatives and Pharmaceutical Compositions Containing Them | C3AR1, C5AR1, CCR8 | MAPT 4364/4885ALDH1A1 907/4885PTGS1 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.